Recently, covalent drugs experienced significant renewed interest in drug discovery. This resurgence led to a better understanding of the reactivity relationships required to engage selective covalent bonds between nucleophilic proteins and electrophilic small molecules. As a result, covalent molecules were found to be of great utility for supporting drug discovery and medicinal chemistry programmes. Since 2016 Enamine synthesizes 15 000+ new covalent compounds each year. This greatly contributes to the constant update of available libraries in line with the latest trends in covalent warheads. Join our event on November 30, 2 PM UTC to learn more about the expanding landscape of covalent libraries, and notable case studies.
 

About Organizer: 
Enamine is the leading producer and supplier of building blocks and compound libraries for drug discovery, serving the industry since 1991. The company is a developer of cutting-edge technology for generating ultra-large chemical space for hit discovery (REAL space), with molecules accessible with 80%+ rate, within 3-4 weeks. The technology is based on the world's largest stock of building blocks and proprietary framework for compound library synthesis.